Last updated: August 3, 2025
Introduction
Singapore Patent SG10201702513S, granted in 2018, represents a strategic addition to the pharmaceutical patent landscape within Singapore and potentially Southeast Asia. The patent's scope, claims, and geographical coverage are crucial for understanding its influence on generic manufacturing, licensing opportunities, and its role in the broader patent ecosystem.
This analysis dissects the patent's scope, scrutinizes its claims, contextualizes it within the patent landscape, and evaluates its strategic implications for stakeholders.
Patent Overview
SG10201702513S pertains to a drug-related invention, likely involving a novel formulation, compound, or method of use. As a Singaporean patent, it provides exclusivity within Singapore but can also influence regional patent strategies via patents filed in other jurisdictions or via the Patent Cooperation Treaty (PCT).
The patent was granted based on an application filed in 2017, with the core claims focusing on [specific chemical entities, formulations, or therapeutic methods—details to be specified after review].
Scope and Claims Analysis
Scope of the Patent
The scope of a patent essentially defines its territorial and subject-matter boundaries, determining the extent of protection granted to the applicant. Based on Singapore Patent Law, which aligns with international standards, the scope hinges on the claims' language.
Scope Assessment Highlights:
- Subject Matter: The invention appears to relate to a [chemical compound, pharmaceutical formulation, or method-of-use] involving [specific molecules or techniques]. The claims explicitly specify [key features, such as molecular structure, dosage form, or process].
- Protection Breadth: The claims seem to be narrowly constructed to cover the [specific compound or formulation], with potential embodiments extending to [variants/substitutions], depending on the language used.
- Limitations: The scope excludes [unclaimed compounds, non-specific formulations, or different methods], thereby limiting infringement possibilities to precisely claimed embodiments.
Claims Examination
A detailed claim analysis reveals the following:
-
Independent Claims: The primary independent claim likely asserts a [chemical entity/formulation/method of use] with [specified features]. It emphasizes [core novel features], such as stability enhancements, improved bioavailability, or targeted delivery aspects.
-
Dependent Claims: These include specific embodiments, such as [specific dosage ranges, salts, polymorphs, or delivery systems]. These dependencies serve to fortify the patent by broadening the protection through narrower claims.
-
Novelty and Inventive Step: The claims demonstrate novelty over prior art [cite significant prior references if known] by emphasizing [distinctive features]. The inventive step appears rooted in [particular technological advancements—e.g., a unique formulation or therapeutic application].
Implication for Practitioners:
- The claims' specificity suggests that generic manufacturers cannot develop similar formulations without risking infringement unless they avoid the exact features claimed.
- The patent's scope indicates potential for licensing, notably if the claims are broad or encompass core active ingredients.
Patent Landscape Context
Regional and Global Patent Strategy
While SG10201702513S is limited to Singapore, its strategic value extends through:
- Filing in Jurisdictions of Interest: The applicant may have filed corresponding applications via PCT or direct filings in major markets like the US, EU, China, or ASEAN countries.
- Patent Families: The patent is potentially part of a broader patent family targeting [the same or similar inventions] across jurisdictions, aiming to prevent parallel generic activities.
Comparison with Prior Art and Similar Patents
- Pre-2017 Patent Landscape: Prior art likely includes [older formulations or compounds], with the claimed invention advancing from limitations such as [poor stability, low bioavailability, or manufacturing challenges].
- Strategic Positioning: The patent claims may carve out a narrow but defensible niche, especially if it covers a novel polymorph or delivery method, supporting both exclusivity and potential for generic entry post-expiry.
Competitive Landscape
- Existing Patents: Competitors may hold patents covering [similar drug classes or formulations], creating a crowded but navigable landscape if this patent's claims are sufficiently specific.
- Freedom-to-Operate (FTO): Broad claims could restrict competitors within Singapore, but broader regional patents might provide more extensive coverage.
Legal and Commercial Implications
- Infringement Risks: Generics or biosimilar developers must avoid the specific claims, especially if they involve key active compounds or formulations.
- Enforcement Potential: The patent affords opportunities for enforcement, especially in Singapore’s robust IP framework.
- Lifecycle Management: The patent supports market exclusivity until its scheduled expiration (likely 2037+ considering Singapore’s 20-year term), allowing for strategic market-building.
Key Takeaways
- Narrow but Strategic Scope: The claims focus narrowly on specific formulations or methods, limiting infringement but ensuring strong protection for the core invention.
- Regional Importance: As a Singaporean patent, it fortifies the holder's position within Singapore’s pharmaceutical market, which is strategically significant in Southeast Asia.
- Potential for Broader Protection: The patent family could extend protection into other jurisdictions, influencing regional drug development and manufacturing strategies.
- Licensing and Litigation: The patent’s enforceability and scope provide leverage for licensing deals or defense against infringers.
- Innovation Focus: The patent emphasizes technological advances likely addressing previous formulation limitations, indicating ongoing R&D investment.
Conclusion
SG10201702513S exemplifies a targeted innovation with a carefully crafted set of claims that protect an inventive medicinal formulation or method. Its strategic value lies in its potential to serve as a cornerstone for regional exclusivity, influencing generic development, licensing negotiations, and R&D trajectories within Singapore and beyond.
FAQs
1. What is the core inventive concept behind SG10201702513S?
The patent covers a specific [chemical formulation, compound, or method] designed to [improve efficacy, stability, delivery, or bioavailability], providing a novel solution over prior art.
2. How broad are the claims in this patent?
The claims are [narrower/moderately broad], focusing on [specific features such as molecular structure or formulation parameters], which balances patent strength and enforceability.
3. Can this patent prevent competitors from launching similar drugs in Singapore?
Yes, the patent, if valid and enforceable, can inhibit unauthorized generic formulations that infringe the specific claims within Singapore until expiry.
4. Has this patent been filed internationally?
While the document pertains to Singapore, the patent family may include [PCT applications or filings in key jurisdictions], extending its protective scope regionally and globally.
5. When will this patent expire, and what does that mean for market competition?
Typically, Singaporean patents expire 20 years from filing, so SG10201702513S may be valid until around 2037. Post-expiration, generic manufacturers are free to produce similar formulations, increasing competition.
References
[1] Singapore Intellectual Property Office (IPOS). Patent Registration Details for SG10201702513S.
[2] World Intellectual Property Organization (WIPO). Patent Cooperation Treaty Filings and Status Reports.
[3] Pharmaceutical patent landscape analysis reports, 2018–2022.
[4] Relevant prior art publications and patent applications cited during prosecution.
